Trials / Completed
CompletedNCT06451640
A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps
A Multicenter, Randomized, Ongoing Trial Evaluating the Long-term Safety and Efficacy of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy and safety of TQC2731 injection in the treatment of chronic sinusitis with nasal polyps.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 210mg of TQC2731 injection | TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody. |
| DRUG | 420mg of TQC2731 injection | TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody. |
Timeline
- Start date
- 2024-07-04
- Primary completion
- 2025-10-17
- Completion
- 2025-10-17
- First posted
- 2024-06-11
- Last updated
- 2025-11-20
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06451640. Inclusion in this directory is not an endorsement.